Artiva Biotherapeutics, Inc. 4

Director Brian Daniels received a stock option award for 13,750 shares of Artiva Biotherapeutics, Inc. common stock at a $10.88 exercise price as director compensation.

On September 8, 2026, Director Brian Daniels was granted a stock option covering 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share, representing a potential value of approximately $149,600 if fully exercised at the grant price. The option is a director compensation award that will vest in full on the earlier of September 8, 2027, or the date of the company’s 2027 annual stockholder meeting, and has an expiration date of September 7, 2036. Following this grant, Daniels holds 13,750 derivative securities (stock options) corresponding to 13,750 shares of common stock on a direct ownership basis; no other transactions or sales were reported in this filing.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-385414

Alert Tier

5